Key result
Lower sRAGE plasma levels are linked to acute coronary syndrome compared to stable angina.
Why the study?
The role of plasma soluble receptor for advanced glycation end products (sRAGE) in patients with acute coronary syndrome and its diagnostic efficacy for acute events was evaluated.
Are sRAGE plasma levels associated with the clinical presentation of acute coronary syndrome versus stable angina in patients with coronary artery disease?
Observational (n=860)
Are sRAGE plasma levels associated with the clinical presentation of acute coronary syndrome versus stable angina in patients with coronary artery disease?
Answers are grounded in this paper and cite their sources.
Lower plasma levels of sRAGE are associated with acute coronary syndromes compared to stable angina, suggesting it may serve as a biomarker for vulnerable plaque destabilization.
Receptor for Advanced Glycation End-products (RAGE) is a multi-ligand receptor ubiquitous present on epithelial, neuronal, vascular and inflammatory cells, usually expressed at low levels in homeostasis and to increased degrees at sites of stress or injury. The aim of the present study was to evaluate sRAGE plasma levels in patients with Acute Coronary Syndrome (ACS) and to assess its diagnostic efficacy in identification of patients with acute events. Plasma levels of sRAGE were determined in 860 patients with Coronary Artery Disease (CAD): 530 patients presented stable angina and 330 were observed during acute ischemic event (147 with unstable angina and 183 with myocardial infarction). sRAGE plasma levels were significantly lower in patients with ACS than in patients with stable angina: [median 584 pg/mL (IQR: 266-851 pg/mL) in MI patients, median 769 pg/mL (IQR: 394-987 pg/mL) in patients with unstable angina, median 834 pg/mL (IQR 630-1005 pg/mL) in patients with stable angina; P < 0.001]. sRAGE levels did not differ among ACS patients stratified by the extent of coronary artery disease. In conclusion, this study confirm the role of sRAGE in activation and progression of inflammatory process and suggests the possibility that sRAGE can be considered an indicator of destabilization of vulnerable plaque.
No takes yet. Share an insight, caveat, or question.
Falcone et al. (2013) conducted an observational in Coronary Artery Disease (n=860). sRAGE plasma levels vs. Stable angina was evaluated on sRAGE plasma levels (p=< 0.001). Plasma levels of sRAGE were significantly lower in patients with acute coronary syndrome (median 584 pg/mL for MI, 769 pg/mL for unstable angina) than stable angina (834 pg/mL; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: